The Food and Drug Administration on Tuesday approved four drugmakers' generic versions of Strattera — Eli Lilly's attention-deficit/hyperactivity disorder drug.
Apotex, Teva Pharmaceuticals, Aurobindo Pharma and Glenmark Pharmaceuticals may now market and sell their generic versions of the drug to both children and adults.
"Today's approvals mark an important step forward in bringing consumers additional treatments that have met the FDA's rigorous standards," Kathleen Uhl, MD, director of the agency's Office of Generic Drugs, said in a news release. "Quickly bringing generics to market so patients have more options to treat their conditions is a top priority for the FDA."
More articles on supply chain:
Pharma spent $78M on lobbying so far this year: 4 statistics
Mallinckrodt considers sale of generic drug unit: 4 things to know
Medicare patients don't see benefits of drug rebates, says researchers